35.74
0.05 (0.15%)
| Previous Close | 35.68 |
| Open | 35.78 |
| Volume | 439,670 |
| Avg. Volume (3M) | 571,368 |
| Market Cap | 1,742,199,168 |
| Price / Sales | 3.16 |
| Price / Book | 3.17 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| Profit Margin | -8.70% |
| Operating Margin (TTM) | -6.39% |
| Diluted EPS (TTM) | -0.830 |
| Quarterly Revenue Growth (YOY) | 17.90% |
| Total Debt/Equity (MRQ) | 16.59% |
| Current Ratio (MRQ) | 3.62 |
| Operating Cash Flow (TTM) | 10.40 M |
| Levered Free Cash Flow (TTM) | 11.41 M |
| Return on Assets (TTM) | -3.51% |
| Return on Equity (TTM) | -8.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | AtriCure, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -1.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.40 |
|
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 3.18% |
| % Held by Institutions | 105.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 61.00 (Canaccord Genuity, 70.70%) | Buy |
| Median | 40.00 (11.94%) | |
| Low | 36.00 (Oppenheimer, 0.74%) | Buy |
| Average | 43.40 (21.45%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 33.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 17 Dec 2024 | 40.00 (11.94%) | Buy | 31.50 |
| 30 Oct 2024 | 40.00 (11.94%) | Buy | 34.83 | |
| Canaccord Genuity | 09 Dec 2024 | 61.00 (70.70%) | Buy | 33.94 |
| 30 Oct 2024 | 53.00 (48.31%) | Buy | 34.83 | |
| Needham | 30 Oct 2024 | 40.00 (11.94%) | Buy | 34.83 |
| Oppenheimer | 30 Oct 2024 | 36.00 (0.74%) | Buy | 34.83 |
| UBS | 30 Oct 2024 | 40.00 (11.94%) | Buy | 34.83 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| NOZNESKY JUSTIN J | - | 33.31 | -585 | -19,486 |
| Aggregate Net Quantity | -585 | |||
| Aggregate Net Value ($) | -19,486 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 33.31 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NOZNESKY JUSTIN J | Officer | 11 Dec 2024 | Disposed (-) | 585 | 33.31 | 19,486 |
| Date | Type | Details |
|---|---|---|
| 20 Nov 2024 | Announcement | AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference |
| 07 Nov 2024 | Announcement | AtriCure to Participate in the Stifel 2024 Healthcare Conference |
| 29 Oct 2024 | Announcement | AtriCure Reports Third Quarter 2024 Financial Results |
| 28 Oct 2024 | Announcement | AtriCure to Participate in the UBS Global Healthcare Conference |
| 15 Oct 2024 | Announcement | AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management |
| 08 Oct 2024 | Announcement | AtriCure to Announce Third Quarter 2024 Financial Results |
| 01 Oct 2024 | Announcement | AtriCure Receives CE-Mark for the EnCompass® Clamp |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |